-
<![CDATA[Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025]]>
25 Sep 2025 16:11 GMT
… or sequenced with trastuzumab [Herceptin], pertuzumab [Perjeta], and … positive, endocrine-refractory breast cancer setting, where patients … HR-positive metastatic breast cancer cases without PIK3CA … triple negative breast cancer
315P - SYNERGIA breast cancer - …
-
<![CDATA[First-Line Enhertu Combo Gets Priority Review in HER2+ Metastatic Breast Cancer]]>
25 Sep 2025 02:38 GMT
… treatment of a taxane chemotherapy, Herceptin (trastuzumab), and Perjeta — altogether … patients facing HER2-positive metastatic breast cancer, the news release concludes.
… patients with HER2-positive metastatic breast cancer,” by AstraZeneca. News release; …
-
<![CDATA[T-DXd Earns FDA Priority Review in First-Line HER2+ Breast Cancer]]>
24 Sep 2025 21:29 GMT
… metastatic HER2-positive breast cancer.1
The Prescription … a taxane plus trastuzumab (Herceptin) and pertuzumab (THP; … with HER2-positive metastatic breast cancer. News release. AstraZeneca. … with HER2-positive metastatic breast cancer. News release. Daiichi …
-
<![CDATA[FDA Grants Priority Review to First-Line T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer]]>
24 Sep 2025 18:24 GMT
… with a taxane plus trastuzumab (Herceptin) and pertuzumab (THP; n = 387 … patients with HER2-positive metastatic breast cancer. News release. AstraZeneca. September 24 … patients with HER2 positive metastatic breast cancer. News release. Daiichi Sankyo. July …
-
<![CDATA[The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer]]>
24 Sep 2025 17:03 GMT
… consisting of a taxane, trastuzumab (Herceptin), and pertuzumab (n = 387), … patients with HER2-positive metastatic breast cancer. News release. AstraZeneca. September 24 … patients with HER2 positive metastatic breast cancer. News release. Daiichi-Sankyo. …
-
Alkem launches Roche's breast cancer blockbuster biosimilar alternative in India
22 Sep 2025 21:11 GMT
… the launch of its blockbuster breast cancer therapy biosimilar alternative 'Pertuza … HER2-positive breast cancer.
The innovators brand targets the HER2 (Herceptin) protein and …
-
<![CDATA[Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting ]]>
24 Sep 2025 18:10 GMT
… ), a biosimilar to trastuzumab (Herceptin; Genentech), demonstrated favorable efficacy … , lung, colorectal, and metastatic breast cancers.2,3
Herzuma is indicated … combination therapy in adjuvant breast cancer and metastatic breast cancer. As a biosimilar, …
-
Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)
17 Sep 2025 17:44 GMT
… HER2-positive advanced breast cancer patients exhibiting primary … HER2-positive advanced breast cancer cohort. Furthermore, … early breast cancer: final analysis of the HERceptin Adjuvant … HER2 positive breast cancer in 2020. Transl Breast Cancer Res. …
-
<![CDATA[Trastuzumab Pamirtecan Hits Phase 3 PFS End Point in HER2+ Metastatic Breast Cancer]]>
13 Sep 2025 01:32 GMT
… or metastatic breast cancer who previously received trastuzumab (Herceptin) and a … or metastatic, HER2-positive breast cancer who previously received treatment … , hormone receptor positive metastatic breast cancer (DYNASTY-Breast02). ClinicalTrials.gov …
-
Real-World Evidence Supports Biosimilar HLX02 in Metastatic Breast Cancer
12 Sep 2025 02:00 GMT
… the high cost of Herceptin (reference trastuzumab) has long … cost-effective alternative to Herceptin. “Our findings support … that transitioning patients from Herceptin to HLX02 is unlikely … with HER2-positive advanced breast cancer: a retrospective real-world …
About
© 1995-2025